Is Catheter Precision, Inc. overvalued or undervalued?

As of 15 August 2022, the valuation grade for Catheter Precision, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently deemed overvalued, primarily due to its negative earnings and poor performance metrics. The Price to Book Value stands at 0.29, while the EV to EBITDA is at -1.40, and the ROCE is a concerning -61.81%.
In comparison to its peers, Catheter Precision's valuation ratios are notably worse; for instance, Cardio Diagnostics Holdings, Inc. has an EV to EBITDA of 0.5065, while Vivos Therapeutics, Inc. shows an EV to EBITDA of -1.0143. The stark contrast in these ratios highlights Catheter Precision's relative weakness in the market. Additionally, the company's stock has underperformed significantly, with a one-year return of -95.54% compared to a 10.26% return for the S&P 500, further reinforcing the notion that it is overvalued at its current price of $0.27.